Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AVMXYOTCMKTS:BCYPOTCMKTS:OSIRNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVMXYAVITA MED LTD/S$7.89$7.89$1.06▼$8.58$651.87M1.28183,275 shsN/ABCYPBig Cypress Acquisition$8.44-19.2%$8.44$8.21▼$12.90$124.84MN/A160,982 shs15.34 million shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/APRMEPrime Medicine$2.65+9.5%$1.54$1.11▼$6.75$347.93M1.551.48 million shs2.65 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVMXYAVITA MED LTD/S0.00%0.00%0.00%0.00%0.00%BCYPBig Cypress Acquisition0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%PRMEPrime Medicine+9.50%+47.22%+108.66%+33.17%-47.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/AN/AN/AN/ABCYPBig Cypress AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRMEPrime Medicine3.907 of 5 stars4.41.00.00.03.45.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVMXYAVITA MED LTD/S 0.00N/AN/AN/ABCYPBig Cypress Acquisition 0.00N/AN/AN/AOSIROsiris Therapeutics 0.00N/AN/AN/APRMEPrime Medicine 2.75Moderate Buy$10.08280.50% UpsideCurrent Analyst Ratings BreakdownLatest AVMXY, OSIR, PRME, and BCYP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVMXYAVITA MED LTD/S$5.51M118.31N/AN/A$0.26 per share30.35BCYPBig Cypress AcquisitionN/AN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/APRMEPrime Medicine$3.85M90.47N/AN/A$1.37 per share1.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVMXYAVITA MED LTD/S-$24.75M-$0.39N/A∞N/AN/AN/AN/AN/ABCYPBig Cypress Acquisition-$10KN/A0.00N/AN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/ABCYPBig Cypress AcquisitionN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4554.57%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVMXYAVITA MED LTD/SN/A5.505.33BCYPBig Cypress AcquisitionN/A6.136.13OSIROsiris TherapeuticsN/AN/AN/APRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVMXYAVITA MED LTD/S0.01%BCYPBig Cypress Acquisition60.21%OSIROsiris Therapeutics0.28%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipAVMXYAVITA MED LTD/SN/ABCYPBig Cypress AcquisitionN/AOSIROsiris Therapeutics43.40%PRMEPrime Medicine22.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVMXYAVITA MED LTD/S5582.62 millionN/ANot OptionableBCYPBig Cypress Acquisition1714.79 millionN/ANot OptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableAVMXY, OSIR, PRME, and BCYP HeadlinesRecent News About These CompaniesPrime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 SharesJune 24 at 4:53 AM | insidertrades.comInsider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Purchases 21,000 Shares of StockJune 23, 2025 | marketbeat.comHead to Head Survey: Voyager Therapeutics (NASDAQ:VYGR) vs. Prime Medicine (NYSE:PRME)June 20, 2025 | americanbankingnews.comPrime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment OpportunityJune 17, 2025 | tipranks.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in StockJune 17, 2025 | insidertrades.comInsider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of StockJune 16, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in StockJune 12, 2025 | marketbeat.comTwo Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)June 10, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)May 30, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comPrime Medicine's (PRME) "Neutral" Rating Reaffirmed at CitigroupMay 28, 2025 | marketbeat.comCitigroup Downgrades Prime Medicine (PRME)May 28, 2025 | msn.comCiti Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market UncertaintyMay 27, 2025 | msn.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21, 2025 | nasdaq.comCEO among 25% of staff out the door at cash-strapped PrimeMay 20, 2025 | thepharmaletter.comTPrime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staffMay 20, 2025 | fiercebiotech.comFPrime Medicine claims ‘proof of concept,’ but lays off staff in pivotMay 20, 2025 | biopharmadive.comBCRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staffMay 20, 2025 | bostonglobe.comBPrime Medicine drops after cutting CGD program amid restructuringMay 20, 2025 | msn.comPrime Medicine stock plummets amid restructuring and leadership changesMay 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVMXY, OSIR, PRME, and BCYP Company DescriptionsAVITA MED LTD/S OTCMKTS:AVMXYAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Big Cypress Acquisition OTCMKTS:BCYP$8.44 -2.01 (-19.23%) As of 10/22/2021Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Prime Medicine NYSE:PRME$2.65 +0.23 (+9.50%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.65 0.00 (-0.04%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
